RT Journal Article
T1 Supervised Exercise Immediately After Bariatric Surgery: the Study Protocol of the EFIBAR Randomized Controlled Trial.
A1 Artero, Enrique G
A1 Ferrez-Márquez, Manuel
A1 Torrente-Sánchez, María José
A1 Martínez-Rosales, Elena
A1 Carretero-Ruiz, Alejandro
A1 Hernández-Martínez, Alba
A1 López-Sánchez, Laura
A1 Esteban-Simón, Alba
A1 Romero Del Rey, Andrea
A1 Alcaraz-Ibáñez, Manuel
A1 Rodríguez-Pérez, Manuel A
A1 Villa-González, Emilio
A1 Barranco-Ruiz, Yaira
A1 Martínez-Forte, Sonia
A1 Castillo, Carlos
A1 Gómez Navarro, Carlos
A1 Aceituno Cubero, Jesús
A1 Reyes Parrilla, Raúl
A1 Aparicio Gómez, José A
A1 Femia, Pedro
A1 Fernández-Alonso, Ana M
A1 Soriano-Maldonado, Alberto
K1 Bariatric surgery
K1 Exercise
K1 Obesity
K1 Protocol
K1 Randomized controlled trial (RCT)
AB Previous studies have investigated weight loss caused by exercise following bariatric surgery. However, in most cases, the training program is poorly reported; the exercise type, volume, and intensity are briefly mentioned; and the sample size, selection criteria, and follow-up time vary greatly across studies. The EFIBAR study aims to investigate over 1 year the effects of a 16-week supervised exercise program, initiated immediately after bariatric surgery, on weight loss (primary outcome), body composition, cardiometabolic risk, physical fitness, and quality of life in patients with severe/extreme obesity. The EFIBAR study is a parallel-group, superiority, randomized controlled trial (RCT), comprising 80 surgery patients. Half of the participants, randomly selected, perform a 16-week supervised exercise program, including both strength and aerobic training, starting immediately after the surgery (7-14 days). For each participant, all primary and secondary outcomes are measured at three different time points: (i) before the surgery, (ii) after the intervention (≈4 months), and (iii) 1 year after the surgery. The EFIBAR study will provide new insights into the multidimensional benefits of exercise in adults with severe/extreme obesity following bariatric surgery. EFIBAR randomized controlled trial was prospectively registered at Clinicaltrials.gov (NCT03497546) on April 13, 2018.
YR 2021
FD 2021-07-15
LK http://hdl.handle.net/10668/18204
UL http://hdl.handle.net/10668/18204
LA en
DS RISalud
RD Jul 4, 2025